Navigation Links
The Market for Non-Small-Cell Lung Cancer (NSCLC) Will Grow to $7 Billion in 2022, Fuelled by the Entry of Twelve Novel Agents
Date:12/12/2013

BURLINGTON, Mass., Dec. 12, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the entry of twelve new therapies into the non-small-cell lung cancer (NSCLC) drug market will drive the market's growth from $4.9 billion in 2012 to over $7 billion in 2022. The approval of three immunotherapies, the entry of second generation ALK and EGFR inhibitors, as well as continued uptake of Pfizer's Xalkori and EGFR inhibitors particularly in the advanced/metastatic first-line treatment setting will drive the growth of the NSCLC drug market. This market growth will occur despite the generic erosion of key branded current therapies including Eli Lilly's Alimta and Genentech/Roche/Chugai/Astellas's Tarceva.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Pharmacor Non-Small-Cell Lung Cancer advisory service also finds that treatment of NSCLC is becoming increasingly personalized, driven by the accumulation of positive data of current and novel therapies in molecularly defined populations. The expected approvals of Novartis's ceritinib (LDK-378) and Chugai/Roche's alectinib for Xalkori-treated patients further advances the personalized treatment approach in NSCLC, offering a targeted second-line standard-of-care therapy for ALK-translocation positive patients.

"The majority of the agents in the NSCLC pipeline are being developed to target specific molecular targets," said Decision Resources Business Insights Analyst Orestis Mavroudis-Chocholis, Ph.D. "In the next ten years, we expect the launch of seven agents positioned to treat specific molecularly defined patient subpopulations—Pfizer's dacomitinib, Genentech/Roche/Chugai's onartuzumab, ceritinib, alectinib, Bristol-Myers Squibb/Ono Pharmaceutical's nivolumab, Merck's MK-3475 (formerly known as lambrolizumab) and AstraZeneca's selumetinib."

The report also finds that the unmet needs for more efficacious therapies for squamous-cell NSCLC patients and those harboring KRAS mutations will be addressed to some extent by the approval of novel therapies, Eli Lilly's necitumumab and selumetinib, respectively. However, significant unmet need remains particularly for these underserved patient populations.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Rapid Fire Marketing Funds Development of Second Generation Vapor Inhaler
2. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
3. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
4. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
5. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
6. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
7. Ophthalmic Drugs: World Market Prospects 2012-2022
8. OTC Pharmaceuticals: Global Industry Almanac, MarketLine
9. ResearchMoz: The World Anesthesia Drug Market (General, Local, Adjunctive) - Market Research Report
10. Endocrinology Market to 2018 - Advanced Injection Devices for Growth Hormone and Somatostatin will Improve Ease of Use for Patients
11. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... MINNEAPOLIS , April 20, 2017  Cogentix ... company focused on providing the Urology, Uro/Gyn and ... reported that Ash Keswani has joined the Company ... In this newly created position, Mr. Keswani will ... and CEO. "Our organization is delighted ...
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Market and Increasing Usage of Complex Biologics during the Forecast Period" ... ... 20 Billion in 2015 to around USD 26 Billion by 2020. ... by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics ...
(Date:4/20/2017)... 20, 2017 Eyevensys, a private ... non-viral gene expression technology that enables the safe, local, ... address a wide range of ophthalmic diseases, announces it ... products Regulatory Agency (MHRA) to advance its technology into ... ...
Breaking Medicine Technology:
(Date:4/29/2017)... (PRWEB) , ... April 29, 2017 , ... ... celebrate the profession and recognize the positive impact veterinarians have on animal health ... and the World Organization for Animal Health (OIE) choose a theme each year ...
(Date:4/28/2017)... NC (PRWEB) , ... April 28, 2017 , ... ... announce its new partnership with the Home Care Association of America (HCAOA). This ... and Private Duty Accreditation services, as well as discounts on Accreditation University (AU) ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Beginning in ... of their formulas. This begins with the popular ClearLungs Extra Strength formula. To ensure ... changing the formula in the following ways:, , Removal of ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... distribution of the GlycoMark test throughout the Northeast U.S. , GlycoMark is ... with diabetes. The GlycoMark test provides a clinically proven one- to two-week measure ...
(Date:4/28/2017)... Fairfax, VA (PRWEB) , ... April 28, 2017 , ... ... elected volunteer board members and officers for 2017-2018. The annual board election process has ... serving on a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, ...
Breaking Medicine News(10 mins):